Oncotelic Announces Release of Pet2DAO Tokens PDAO

AGOURA HILLS, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, Pancreatic Ductal Adenocarcinoma, Diffuse Intrinsic Pontine Glioma, and COVID-19, today announced the process for the shareholders of the Company for the release of Pet2DAO LLC (“Pet2DAO”) tokens called PDAO. Pet2DAO is a wholly owned subsidiary of the Company. Eligible shareholders can claim PDAO tokens to participate in the subsidiary to make proposals and vote on such proposals. Eligible shareholders shall have 4 months from April 1, 2023, i.e. through July…